Safety and efficacy of generic daclatasvir-sofosbuvir as a pan genotypic regimen for HCV-infected patients in Bandung, Indonesia

被引：0
|
作者：
Bestari, Muhammad Begawan [1 ]
Nugraha, Eka Surya [1 ]
Abdurachman, Siti Aminah [1 ]
机构：
[1] Univ Padjadjaran, Hasan Sadikin Gen Hosp, Dept Internal Med GI Hepatol, Bandung, Indonesia
来源：
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | 2018年 / 33卷
关键词：
hepatitis C; pan genotypic; treatment; sofosbuvir; daclatasvir;
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
OE-0189 (P
引用
收藏
页码：443 / 443
页数：1
相关论文
共 50 条
  • [21] Efficacy and safety of Elbasvir/Grazoprevir in a large real-life cohort of HCV-infected patients
    Gambato, M.
    Spinetti, A.
    Pasulo, L.
    D'ambrosio, R.
    Puoti, M.
    Schiavini, M.
    Fabris, P.
    Sacchi, P.
    Gulminetti, R.
    Carolo, G.
    Scotton, P.
    Franceschet, I.
    Vinci, M.
    Vigano, M.
    Lobello, S.
    Zuin, M. G.
    Aghemo, A.
    Rumi, M.
    Carrara, M.
    Manfrin, V.
    Uberti-Foppa, C.
    Panese, S.
    Cattelan, F.
    Paon, V.
    Pan, A.
    Spinelli, O.
    Monforte, A. D'arminio
    Colli, A.
    Spinzi, G.
    Russo, F. P.
    Chemello, L.
    Vincenzi, V.
    Grossi, P. A.
    Buscarini, E.
    Cardaci, G.
    Soria, A.
    Menzaghi, B.
    Mendeni, M.
    Degasperi, E.
    Soffredini, R.
    Colpani, M.
    Comi, L.
    Zuccaro, V.
    Zaltron, S.
    Gori, A.
    Del Poggio, P.
    Giorgini, A.
    Capretti, A.
    Memoli, M.
    Pigozzi, M. G.
    DIGESTIVE AND LIVER DISEASE, 2019, 51 : E55 - E56
  • [22] Comparison between safety and efficacy of two treatment regimens for pediatric patients with chronic hepatitis C virus: Sofosbuvir/ledipasvir versus sofosbuvir/daclatasvir regimen
    Ahmed, Mohamed
    Hanno, Abdelfattah
    Hamouda, Soraya
    Abdelgawad, Manal
    Abouelkhier, Hossam
    JOURNAL OF HEPATOLOGY, 2019, 70 (01) : E208 - E208
  • [23] Safety and Efficacy of Ledipasvir/Sofosbuvir on Hepatitis C Eradication in HCV/HIV Co-infected Patients
    He, Xiaoping
    Hopkins, Lynne
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2017, 112 : S1497 - S1498
  • [24] Safety and efficacy of Sofosbuvir/Velpatasvir with and without Ribavirin in genotype 3HCV-infected patients with cirrhosis
    Ferret, M. B.
    Pineda, J.
    Panero, J. L. C.
    Rodriguez, M.
    Morillas, R. M.
    Pascasio, J. M.
    Rivero, A.
    Mcnabb, B.
    Zhang, G.
    Camus, G.
    Stamm, L.
    Brainard, D.
    Subramanian, M.
    Carrion, J. A.
    Andrade, R. J.
    Amado, L. E. M.
    Turnes, J.
    Lens, S.
    Casado, M.
    Esteban, R.
    JOURNAL OF HEPATOLOGY, 2018, 68 : S20 - S21
  • [25] EFFICACY AND SAFETY OF PEGUILATED INTERFERON AND RIBAVIRIN IN HCV-INFECTED PATIENTS WITH ADVANCED CIRRHOSIS AWAITING LIVER TRANSPLANTATION
    Feldner, A. C. C. A.
    Ribeiro, T. C. R.
    Bragagnolo, M. A., Jr.
    Seda-Neto, J.
    Brito, J. D. R.
    Trindade, L. Z.
    Oliveira, E. M. G.
    Parise, E. R.
    Kondo, M.
    JOURNAL OF HEPATOLOGY, 2010, 52 : S107 - S107
  • [26] SAFETY AND EFFICACY OF TREATMENT WITH ONCE-DAILY LEDIPASVIR/SOFOSBUVIR (90/400 MG) FOR 12 WEEKS IN GENOTYPE 1 HCV-INFECTED PATIENTS WITH SEVERE RENAL IMPAIRMENT
    Lawitz, Eric
    Landis, Charles S.
    Maliakkal, Benedict J.
    Bonacini, Maurizio
    Ortiz-Lasanta, Grisell
    Zhang, Jie
    Mogalian, Erik
    De-Oertel, Shampa
    Osinusi, Anu O.
    Brainard, Diana M.
    McHutchison, John G.
    Yip, Christina Sze Man
    Huang, Hai Cheng
    Flamm, Steven L.
    Gordon, Stuart C.
    Gane, Edward J.
    GUT, 2018, 67 : A99 - A100
  • [27] ENDURANCE-3: safety and efficacy of glecaprevir/pibrentasvir compared to sofosbuvir plus daclatasvir in treatment-naive HCV genotype 3-infected patients without cirrhosis
    Foster, G. R.
    Gane, E.
    Asatryan, A.
    Asselah, T.
    Ruane, P. J.
    Pol, S.
    Poordad, F.
    Stedman, C. A.
    Dore, G.
    Roberts, S. K.
    Kaita, K.
    Vierling, J.
    Vargas, H. E.
    Kort, J.
    Lin, C. -W.
    Liu, R.
    Ng, T.
    Mensa, F.
    JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S33 - S33
  • [28] Safety and Efficacy of Treatment with Once-Daily Ledipasvir/Sofosbuvir (90/400 mg) for 12 Weeks in Genotype 1 HCV-Infected Patients with Severe Renal Impairment
    Lawitz, Eric
    Landis, Charles S.
    Maliakkal, Benedict J.
    Bonacini, Maurizio
    Ortiz-Lasanta, Grisell
    Zhang, Jie
    Mogalian, Erik
    De-Oertel, Shampa
    Osinusi, Anu O.
    Brainard, Diana M.
    McHutchison, John G.
    Flamm, Steven L.
    Gordon, Stuart C.
    Gane, Edward J.
    HEPATOLOGY, 2017, 66 : 848A - 848A
  • [29] Safety and Efficacy of Treatment with Daily Sofosbuvir 400 mg + Ribavirin 200 mg for 24 Weeks in Genotype 1 or 3 HCV-Infected Patients with Severe Renal Impairment
    Martin, Paul
    Gane, Edward J.
    Ortiz-Lasanta, Grisell
    Liu, Lin
    Sajwani, Karim
    Kirby, Brian
    Denning, Jill M.
    Stamm, Luisa M.
    Brainard, Diana M.
    McHutchison, John G.
    Lawitz, Eric
    Gordon, Stuart C.
    Robson, Richard A.
    HEPATOLOGY, 2015, 62 : 765A - 766A
  • [30] Clinical experience with dolutegravir/abacavir/lamivudine in HIV-HCV co-infected patients treated with a sofosbuvir-based regimen-safety and efficacy
    Johnson, Tamara M.
    Sison, Raymund
    Fallon, James P.
    Shukla, Prerak P.
    Bhattarai, Sristi
    Galang, Herbert
    Habeeb, Richard
    Slim, Jihad
    HIV CLINICAL TRIALS, 2016, 17 (06): : 242 - 245
12345